Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.58 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.49 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | HCK | P08631 | 1/20 | 0.48 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.46 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5460323 | 0.85 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL5475413 | 0.83 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL5453772 | 0.79 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL5161577 | 0.79 | MAPK13 (0.50) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL5482295 | 0.78 | MAPK13 (0.49) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL937570 | 0.75 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL5161665 | 0.75 | MAPK13 (0.55) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL23201785 | 0.73 | MAPK14 (1.00) | MAPK14MAPK13 | |
| SCHEMBL5460419 | 0.72 | MAPK14 (0.50) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL14544028 | 0.72 | MAPK14 (0.46) | MAPK14MAPK13MAPK12MAPK11PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082898-A1 | 5 Amino-2-carbonylthiophene derivatives for use as p38 map kinase inhibitors in the treatment of inflammatory diseases | ASTEX THERAPEUTICS LIMITED (GB) | 2007-04-12 | — | — | US | claimed |
| JP-2006522784-A | — | — | 2006-10-05 | — | — | JP | claimed |
| WO-2006040569-A1 | THIOPHENE AMIDE COMPOUNDS FOR USE IN THE TREATMENT OR PROPHYLAXIS OF CANCERS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-04-20 | — | — | WO | claimed |
| EP-1615907-A1 | 5-AMINO-2-CARBONYLTHIOPHENE DERIVATIVES FOR USE AS P38 MAP KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES | Astex Therapeutics Limited (GB) | 2006-01-18 | — | — | EP | claimed |
| WO-2004089929-A1 | 5-AMINO-2-CARBONYLTHIOPHENE DERIVATIVES FOR USE AS P38 MAP KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES | ASTEX THERAPEUTICS LIMITED (GB) | 2004-10-21 | — | — | WO | claimed |
| US-20070082898-A1 | 5 Amino-2-carbonylthiophene derivatives for use as p38 map kinase inhibitors in the treatment of inflammatory diseases | ASTEX THERAPEUTICS LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| US-20070082898-A1 | 5 Amino-2-carbonylthiophene derivatives for use as p38 map kinase inhibitors in the treatment of inflammatory diseases | ASTEX THERAPEUTICS LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| US-20070082898-A1 | 5 Amino-2-carbonylthiophene derivatives for use as p38 map kinase inhibitors in the treatment of inflammatory diseases | ASTEX THERAPEUTICS LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| WO-2006040569-A1 | THIOPHENE AMIDE COMPOUNDS FOR USE IN THE TREATMENT OR PROPHYLAXIS OF CANCERS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-04-20 | — | — | WO | disclosed |
| EP-1615907-A1 | 5-AMINO-2-CARBONYLTHIOPHENE DERIVATIVES FOR USE AS P38 MAP KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES | Astex Therapeutics Limited (GB) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089929-A1 | 5-AMINO-2-CARBONYLTHIOPHENE DERIVATIVES FOR USE AS P38 MAP KINASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY DISEASES | ASTEX THERAPEUTICS LIMITED (GB) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082898-A1 | 5 Amino-2-carbonylthiophene derivatives for use as p38 map kinase inhibitors in the treatment of inflammatory diseases | CNKSR1, NOX5, NOX1 | MAPK14 168/4885MAPK13 95/4885MAPK12 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.